Clinical Trials Logo

Stroke, Ischemic clinical trials

View clinical trials related to Stroke, Ischemic.

Filter by:

NCT ID: NCT06213285 Enrolling by invitation - Atrial Fibrillation Clinical Trials

APPEND-CT Registry

APPEND-CT
Start date: February 14, 2024
Phase:
Study type: Observational

The APPEND-CT registry is an investigator-driven multicenter retrospective observational database intended to compile cardiac CT follow-up data after Watchman FLX device implantation and function as a platform for answering clinical and research questions within LAAC follow-up. The derived studies should support therapeutic decision-making, improve risk-stratification in LAAC and help generate hypotheses for potential future clinical intervention trials.

NCT ID: NCT06200025 Completed - Stroke, Ischemic Clinical Trials

Virtual Reality in Aphasia Rehabilitation

Start date: October 15, 2021
Phase: N/A
Study type: Interventional

Virtual reality-based aphasia rehabilitation has been shown to improve the language skills of individuals with aphasia in the chronic period after stroke. However, non-immersive or semi-immersive rehabilitation methods have often been adopted in the studies. Considering the importance of the visual given to the patient for naming, it can be thought that full immersive therapy may be more effective. Therefore, the aim of this study was to investigate the effect of cue-based aphasia naming therapy in a fully immersive virtual reality environment on aphasia severity and aphasia-related quality of life and to compare it with standard cue treatments.

NCT ID: NCT06196398 Recruiting - Stroke, Ischemic Clinical Trials

Effects of Medical Treatment of ICAS With Hemodynamic Disorders Based on MR-FFR

Start date: January 1, 2023
Phase:
Study type: Observational

This multicenter prospective cohort study aims to compare the difference in the effects of medical treatment within 1 year between the two groups of ICAS patients divided hemodynamically by Magnetic Resonance Fractional Flow Reserve. PC MRA will be applied for FFR measurement. The primary outcome is the composite of ischemic stroke or death related to the qualifying artery territory for 1 year.

NCT ID: NCT06170944 Not yet recruiting - Stroke, Ischemic Clinical Trials

Effect of Remote Ischemic Preconditioning on Collaterals of Atherosclerosis Stroke

RICAS
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore the influence of chronic RIC on collateral status evaluated by DSA in ischemic stroke patients with LAA etiology.

NCT ID: NCT06165107 Completed - Stroke, Ischemic Clinical Trials

The Association Between Obesity-Related Indicators and Adverse Outcomes in Ischemic Stroke Patients

Start date: January 1, 2012
Phase:
Study type: Observational

The study population comprised patients experiencing acute first-ever ischaemic stroke, with diagnostic criteria established in accordance with the International Classification of Diseases, Ninth Revision. All subjects presented rigorous neuroimaging evidence, including head computed tomography and/or magnetic resonance imaging, which underwent review by two or more experienced neuroradiologists. Adverse outcomes were characterized as compliant endpoint events, encompassing mortality and recurrences. The primary outcome was adverse outcomes and the secondary outcome was recurrence-free survival (RFS).

NCT ID: NCT06155032 Recruiting - Stroke, Ischemic Clinical Trials

Rescue Endovascular Therapy for Progressive Acute Mild Ischemic Stroke With Large Vascular Occlusion

Start date: January 4, 2024
Phase: N/A
Study type: Interventional

Endovascular therapy (EVT) added on best medical management is currently recommended in acute large vascular occlusion (LVO) stroke patients with National Institutes of Health Stroke Scale (NIHSS) score >5. Thus, a sizeable fraction of patients with a minor stroke that do not undergo cerebrovascular screening may experience an early neurological deterioration (END) due to LVO, possibly leading to poor long-term functional outcome. However, whether these patients may still benefit from a rescue EVT is unknown, especially in a late window (>24 hours). In this study, the investigators assume that best medical management plus EVT might be superior than best medical management alone in a late window for minor stroke patients who have experienced an LVO and END. The primary objective of the study was to establish the safety and efficacy of EVT in a late window for minor stroke patients in the anterior circulation who experienced an LVO and END.

NCT ID: NCT06148350 Completed - Stroke, Ischemic Clinical Trials

Frenkel's Exercises for Sub-Acute Ischemic Stroke Patients

Start date: March 5, 2021
Phase: N/A
Study type: Interventional

This single-blinded, randomized controlled was aimed to compare the efficacy of Frenkel's and Conventional Balance Exercises in improving balance and quality of life in patients with subacute ischemic stroke. The participants of Group A received 'Frenkel's Exercises'. In contrast, Group B participants received 'Conventional Balance Exercise' interventions three days/week for 30-60 minutes for four weeks. The data was collected pre and post-treatment on the Berg Balance Scale and Stroke Specific-Quality of Life.

NCT ID: NCT06127602 Recruiting - Stroke, Ischemic Clinical Trials

The REACTplusNMES Trial: A Double-blinded RCT

REACT+NMES
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to compare the effectiveness of 6-weeks of reactive balance training (REACT) with and without neuromuscular electrical stimulation (NMES) to paretic lower limb muscles on biomechanical, clinical, neuromuscular and neuroplastic outcomes of reactive balance control. This project is a Phase-I study and incorporates a double-blinded, randomized controlled trial design. Methods: Forty-six individuals with chronic stroke will be recruited and screened for determining their eligibility for the study. Once enrolled, they will be randomized into either of the two groups: intervention group (23 participants) and control group (23 participants). Both groups will undergo series of pre-training assessments which includes a postural disturbance in the form of a slip- or trip-like perturbations and walking tests in laboratory environment. After the pre-training assessment, individuals will undergo 6-weeks of training (2 hour per session, 2 sessions per week). The intervention group will receive NMES with the REACT training and the control group will receive ShamNMES. NMES will be applied to the different muscle groups of the paretic lower limb using an advanced software which is able to synchronize muscle activation with the time of perturbation onset and according to the phases of gait. After training, both groups will again be tested on all the assessments performed pre training. This study will help us understand the immediate therapeutic and mechanistic effects of REACT+NMES and inform stroke rehabilitation research and clinical practice. Our study will provide foundational evidence for future use of NMES to implement clinically applicable neuromodulation adjuvants to reactive balance training, which could be leveraged for designing more effective future interventions for fall-risk reduction.

NCT ID: NCT06121336 Recruiting - Stroke Clinical Trials

PRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke

PROMISE-BD-100
Start date: March 1, 2023
Phase:
Study type: Observational

The investigators recently identified Brain-derived tau (BD-tau) as a sensitive blood-based biomarker for brain injury in acute ischemic stroke: in patients with acute ischemic stroke, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome. While informing on the relation of BD-tau with imaging-based metrics of brain injury, this cross-sectional study was restricted to BD-tau assessments upon admission and at day 2 and could not inform on key characteristics of the evolution of plasma BD-tau, including when exactly it starts to rise, how long it continues to rise, and how it is determined by infarct characteristics as well as comorbidities. Here, the investigators aim to assess plasma BD-tau every hour from admission to 48 hours after onset to evaluate the hypothesis that BD-tau rises immediately after onset and plateaus between three and 48 hours after onset.

NCT ID: NCT06121219 Active, not recruiting - Stroke, Ischemic Clinical Trials

Effect of Visual Retraining After Stroke

urochester
Start date: May 7, 2024
Phase: N/A
Study type: Interventional

This project is intended to collect data using standard clinical tests and psychophysics to quantify the effect of visual cortical damage on the structure of the residual visual system, visual perception, spatial awareness, and brain function. The investigators will also assess the effect of intensive visual retraining on the residual visual system, processing of visual information and the use of such information in real-world situations following damage. This research is intended to improve our understanding of the consequences of permanent visual system damage in humans, of methods that can be used to reverse visual loss, and of brain mechanisms by which visual recovery is achieved.